Assess the efficacy of endocrine therapy preoperatively in patients who are hormone receptor positive
- Conditions
- Health Condition 1: C00-D49- Neoplasms
- Registration Number
- CTRI/2022/01/039736
- Lead Sponsor
- Amrita institute of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1.Female patients aged 18 years and above.
2.Hormone receptor positive ( >1% estrogen receptor) invasive breast cancer
3.Human epidermal growth factor receptor 2 negative (HER2-ve) breast cancers
4.ECOG performance status 0-1
5.Those who have not received chemotherapy or endocrine therapy for breast cancer in the last 5 years.
6.Those who have paraffin fixed core needle tissue block or biopsy punch available for analysis for proliferative markers
7.Signed informed consent
1.Pregnant or lactating women
2.Prior malignancy
3.Evidence of metastatic disease
4.Locally advanced/ inoperable breast cancer
5.High nodal burden
6.Contraindication to endocrine therapy
7.Inhibit or unwillingness to swallow tablets
8.Patients who are not willing to participate in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method